Endometriosis diagnosis delays and new Ryeqo Yselty drugs in UK New estrogen-blocking drugs Ryeqo and Yselty see tripled prescriptions in England, offering hope after years of diagnostic delays for the 1.5 million women with endometriosis. A significant shift in treatment access for endometriosis patients in the United Kingdom has emerged following a report on prescription trends for two newer medications. The data indicates that the number of women being prescribed these specific estrogen-blocking drugs has tripled in the last year. This increase signals a potential improvement in how the chronic condition is managed, offering relief to millions who have long suffered in silence and pain. The condition remains one of the most overlooked causes of severe pelvic discomfort and infertility across the nation. Endometriosis diagnosis delays persistWomen with endometriosis frequently face profound skepticism from healthcare providers when describing their symptoms. A recent report by the charity Endometriosis UK revealed that eighty-two percent of women had been told by medical professionals that they were exaggerating their condition. The average time to receive a definitive diagnosis after seeing a general practitioner is nine years and four months. This duration has increased from eight years recorded in 2020, highlighting a growing systemic failure in early detection. For women from ethnically diverse backgrounds, the waiting period extends further to eleven years. The condition affects approximately 1.5 million individuals in the UK, causing tissue similar to the uterine lining to grow on ovaries, tubes, bladder, and bowel.Ryeqo Yselty prescription surgePrescriptions for Relugolix combination therapy, marketed as Ryeqo, and linzagolix, sold as Yselty, have risen dramatically in England. NICE reported that more than twelve thousand patients received these medications in the year leading to March. This figure is nearly three times the four thousand one hundred prescriptions issued in the previous year. These drugs work by blocking brain signals that stimulate estrogen production, which fuels the growth of endometriosis tissue. Patients receive these tablets alongside low-dose hormones to mitigate menopausal side effects like hot flushes and bone thinning. The surge in prescriptions reflects increased awareness and a move toward more effective management strategies for complex cases.Impact of chronic pain and mental healthThe psychological toll of being disbelieved and suffering untreated pain is severe for those diagnosed with endometriosis. Chronic pain and depression often create a vicious cycle, worsening each other over time. A BBC survey of over thirteen thousand women with the condition found that half had experienced suicidal thoughts. Careers frequently stall, relationships suffer under strain, and friendships wither as women stay home to manage severe pain. When a diagnosis finally arrives, it often brings mixed emotions of relief, grief, and anger for lost years. Many women are initially treated for anxiety or depression while the physical cause remains undiagnosed, compounding their distress and isolation.New options for fertility and painWhile these new tablets are not a cure, they offer reversible relief that preserves future fertility options. Patients stop the medication to try for a baby, avoiding the irreversible nature of some previous treatments. One patient reported being able to return to work after previously being confined to bed. However, side effects include headaches and the need for bone density monitoring. Hormonal contraception remains the standard first treatment but cannot be used when trying to conceive. Some women in their thirties previously opted for hysterectomies, ending their chance of carrying a child, unaware that removing the womb does not cure endometriosis if the tissue exists outside it.Steps for seeking diagnosisExperts advise keeping a detailed symptom diary for two or three months before a medical appointment. Recording pain levels, bowel symptoms, and missed work days creates a record harder to dismiss than verbal accounts. Patients should directly ask if they have endometriosis and mention family history, as the condition runs in families. NICE recommends offering a transvaginal ultrasound to all with suspected cases, even if physical exams are normal. Patients should be aware that a normal ultrasound does not rule out the condition, as smaller patches often do not appear on scans.